Stability in mRNA-LNP Formulations

Published on: 
Pharmaceutical Technology, The Real Message Behind Commercial mRNA Products, April 2023 eBook, Volume 2023 eBook, Issue 3
Pages: 22–25

Lipids aren’t the only important ingredients influencing stability and in vivo performance.

For messenger RNA (mRNA) therapeutics and vaccines formulated as lipid nanoparticles (LNPs), the excipients receiving the most attention are the encapsulating lipids. While these compounds are crucial to the stability and delivery of mRNA-LNPs, the non-lipid excipients also play crucial roles in the function of final drug products. They impact the morphology and stability of these delivery systems, which in turn affects in vivo performance and the overall usefulness of mRNA drugs developed using nanoparticle technology.

Read this article in Pharmaceutical Technology’s The Real Message Behind Commercial mRNA Products eBook.


About the author

Cynthia A. Challener, PhD has been a freelance technical writer for over 20 years and contributes regularly to BioPharm International and Pharmaceutical Technology.

Article details

Pharmaceutical Technology
eBook: The Real Message Behind Commercial mRNA Products
April 2023
Pages: 22–25


When referring to this article, please cite it as Challener, C. A. Excipients Impact Stability in mRNA-LNP Formulations. Pharmaceutical Technology's The Real Message Behind Commercial mRNA Products eBook (April 2023).

Editor’s note: This article was originally published in Pharmaceutical Technology 2023 47 (3).